Nat. Rev. Clin. Oncol. doi: /nrclinonc

Slides:

Advertisements

Similar presentations

Figure 1 Food, nutrition, obesity, physical activity, and the cellular processes linked to cancer Figure 1 | Food, nutrition, obesity, physical activity,

Advertisements

Presented By Sham Mailankody at 2016 ASCO Annual Meeting

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 2 The US Centers for Disease Control and

Figure 1 Concept of the therapeutic index

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 2 Multiscale modelling in oncology

Figure 5 Schematic illustration of different clinical trial designs

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 2 Signalling pathways and physiological domains that are

Figure 1 Key time points in the discovery and development of imatinib for the treatment of chronic myeloid leukaemia (CML) and gastrointestinal stromal.

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 2 Copy-number variations in multiple myeloma

Figure 3 The cell cycle and the role of CDK4/6 inhibition

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 1 Underreporting of treatment-related toxicities by physicians, relative to patients with either advanced-stage lung cancer, or early-stage breast.

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 4 Possible combination therapies CDK4/6 inhibitors

Figure 2 Therapeutic targeting of the PI3K/AKT/mTOR pathway

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 1 CAR-T-cell design

Figure 1 A schematic representation of the HER2 signalling pathway

BIOLOGY 12 Cancer.

Figure 1 Cost of one month of treatment with

Nat. Rev. Urol. doi: /nrurol

Figure 1 Putative anticancer mechanisms of action of PARP inhibitors

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 1 Therapeutic targeting of the B-cell receptor (BCR)

Figure 1 Illustration of three complex somatic mutational phenomena

Figure 3 Drug cycling with collateral sensitivity

Figure 3 Possible modalities for reconciliation of patient's and physician's report of symptomatic treatment-associated toxicities Figure 3 | Possible.

Figure 1 A schematic representation of the role

Figure 1 Balance between proteasomal load and capacity

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 1 NIR fluorescence is more suitable for

Figure 2 Endocrine dysfunction in mitochondrial disease and their associated gene defects Figure 2 | Endocrine dysfunction in mitochondrial disease and.

Figure 1 Critical signalling pathways involved in PDAC pathogenesis

Figure 3 Clinical trial design in charged-particle therapy (CPT)

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 2 Median monthly launch price of a new anticancer drug,

Figure 1 Translocations involved in multiple myeloma

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 2 Key features of gastric cancer subtypes according to The Cancer Genome Atlas (TCGA) Figure 2 | Key features of gastric cancer subtypes according.

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 2 Frequency and overlap of alterations

Figure 2 Cellular pathways implicated in CIPN

Nat. Rev. Nephrol. doi: /nrneph

Figure 6 Proposed model of clonal evolution in multiple myeloma

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 2 Effect of chromosomal instability tolerance

Figure 5 Schematic overview of a clinical decision-support

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 7 Overview of the methodological processes for

Figure 1 Chronic inflammation and DNA damage in people with SLE

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 4 Radiogenomics analysis can reveal relationships

Figure 2 Radiomics in cardiology

Figure 1 Overview of the imaging biomarker roadmap

Figure 3 Determination of the primary site

Figure 4 Molecular signalling and immunological

Pathogenesis of oncogenic HPV

Figure 1 Gene-expression quantification methods

Figure 2 Mechanisms of RET activation in cancer

Identification of RASA1- and NF1-mutated lung cancer cell lines in the CCLE dataset (accessed via the cBioPortal for Cancer Genomics at

Driver pathways and key genes in OSCC

Presentation transcript:

Nat. Rev. Clin. Oncol. doi:10.1038/nrclinonc.2016.122 Figure 4 Recurrent genetic alterations affecting key pathways involved in multiple myeloma Figure 4 | Recurrent genetic alterations affecting key pathways involved in multiple myeloma. Signalling pathways and processes known to be affected in multiple myeloma are involved in the NF-κB, MAPK, plasma-cell differentiation, cell cycle and DNA-damage repair pathways. In this diagram, frequently mutated genes with well-established roles in these signalling pathways have been depicted representing the proteins they encode. Manier, S. et al. (2016) Genomic complexity of multiple myeloma and its clinical implications Nat. Rev. Clin. Oncol. doi:10.1038/nrclinonc.2016.122